English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech (Sci&Research)
Skin Elements Enters Binding Agreement with Holista Colltech To Launch All Natural Skin-Friendly Sanitiser
Apr 03, 2020 17:00 HKT
Avance Clinical 公司的亞太生物科技客戶選擇澳大利亞進行臨床試驗的主要原因
Apr 03, 2020 13:00 HKT
Avance Clinical 公司的亚太生物科技客户选择澳大利亚进行临床试验的主要原因
Apr 03, 2020 13:00 HKT
아방스 클리니컬, APAC 바이오테크 고객사들이 임상시험을 위해 호주를 선택하는 주요 이유 밝혀
Apr 03, 2020 11:30 HKT
애질렉스 바이오랩스, APAC 바이오 분석 서비스 성장 위해 바이오 제약 업계의 리더인 캐롤라인 포퍼 박사 이사장으로 임명
Apr 03, 2020 11:00 HKT
Agilex Biolabs公司任命生物製藥公司負責人Caroline Popper博士任董事會主席,以期推動亞太地區生物分析服務業務增長
Apr 03, 2020 11:00 HKT
Agilex Biolabs公司任命生物制药公司负责人Caroline Popper博士任董事会主席,以期推动亚太地区生物分析服务业务增长
Apr 03, 2020 11:00 HKT
Avance Clinical on Top Reasons APAC Biotech Clients Choose Australia for Clinical Trials
Apr 02, 2020 16:00 HKT
Agilex Biolabs Taps Biopharma Leader Dr Caroline Popper for Board Chair as part of APAC Bioanalytical Services Growth
Apr 02, 2020 15:30 HKT
Dyadic宣布與藥明生物達成非排他性研究許可協議
Mar 31, 2020 12:00 HKT
Dyadic宣布与药明生物达成非排他性研究许可协议
Mar 31, 2020 12:00 HKT
知临集团与Covar医疗携手依托现有Smart-ACTTM平台和Acticule传染病平台研究至少3种2019冠状病毒肺炎(COVID-19)候选再利用药物(SACT-COV19)
Mar 30, 2020 22:12 HKT
知臨集團與Covar醫療攜手依託現有Smart-ACTTM平台和Acticule傳染病平台研究至少3種2019冠狀病毒肺炎(COVID-19)候選再利用藥物(SACT-COV19)
Mar 30, 2020 22:10 HKT
知臨集團將舉行2020年第一季度投資者跟進電話會議以討論最新進展和產品線進度
Mar 30, 2020 21:45 HKT
Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress
Mar 30, 2020 21:44 HKT
Dyadic Announces Nonexclusive Research License with WuXi Biologics
Mar 30, 2020 21:00 HKT
中国生物制药公布2019年年度业绩
Mar 30, 2020 18:22 HKT
中國生物製藥公佈2019年年度業績
Mar 30, 2020 18:21 HKT
Sino Biopharm Announces 2019 Annual Results
Mar 30, 2020 18:25 HKT
AIM ImmunoTech(AIM)宣布進一步加大臨床試驗力度,評估安普利近作為當前新冠肺炎流行病的潛在保護性和早期療法的療效
Mar 26, 2020 20:00 HKT
Next >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: